24-07-2025
Healthpeak Properties Reports Second Quarter 2025 Results
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter ended June 30, 2025.
SECOND QUARTER 2025 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS
Net income of $0.05 per share, Nareit FFO of $0.43 per share, FFO as Adjusted of $0.46 per share, AFFO of $0.44 per share, and Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 3.5%
On July 7, 2025, declared a monthly common stock cash dividend of $0.10167 per share for each of July, August, and September, of 2025 representing cash dividends totaling $0.305 per share for the third quarter, and an annualized dividend amount of $1.22 per share
Second quarter new and renewal lease executions totaled 1.5 million square feet:
Outpatient medical new and renewal lease executions totaled 1 million square feet, with 85% retention and +6% cash releasing spreads on renewals
Subsequent to the second quarter and through July 24, 2025, executed 419,000 square feet of Outpatient medical leases with signed letters of intent on an additional 682,000 square feet
Lab new and renewal lease executions totaled 503,000 square feet, with 87% retention and +6% cash releasing spreads on renewals
Subsequent to the second quarter and through July 24, 2025, executed 55,000 square feet of Lab leases with signed letters of intent on an additional 253,000 square feet
During the second quarter, entered into two new development agreements with a combined projected cost of $148 million to support Northside Hospital's continued outpatient expansion in the Atlanta market
Sold one outpatient medical land parcel in June 2025 and two outpatient medical buildings in July 2025 for combined proceeds of approximately $35 million
Balance Sheet
Net Debt to Adjusted EBITDAre was 5.2x for the quarter ended June 30, 2025
As of July 24, 2025, Healthpeak had approximately $2.3 billion in available liquidity through a combination of unrestricted cash and availability under its revolving credit facility
Launched a redesigned corporate website at to elevate visibility into Healthpeak's competitive advantage and core values
Earned 2025 BOMA Mid Atlantic region TOBY Awards for 833 Chestnut Street (medical category) and Cambridge Discovery Park (life science category); TOBY (The Outstanding Building of the Year) Awards are among the most prestigious recognitions in commercial real estate, honoring commercial building management and operations excellence
Recent corporate impact and sustainability achievements include:
Published a standalone 2024 Environmental Data Report, marking our 14 th consecutive year of environmental performance transparency and reporting
Awarded the Green Lease Leader Platinum designation by the Institute for Market Transformation and the Department of Energy Better Buildings Alliance
Earned LEED Gold certifications for sustainable building design and construction at Callan Ridge in Torrey Pines, California, and 460 Forbes on the Vantage campus in South San Francisco, California, bringing Healthpeak's total LEED-certified square footage to 6.7 million as of June 30, 2025
Named a constituent of the FTSE4Good Index Series for the 14 th consecutive year
To learn more about Healthpeak's commitment to responsible business and view our most recent Corporate Impact Report, please visit
YEAR TO DATE COMPARISON
Nareit FFO, FFO as Adjusted, AFFO, Total Merger-Combined Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "June 30, 2025 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at
The table below outlines the year-over-year three-month and year-to-date total Merger-Combined SS Cash (Adjusted) NOI growth.
DIVIDEND
On July 7, 2025, Healthpeak's Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for each of July, August, and September, of 2025 representing cash dividends totaling $0.305 per share for the third quarter, and an annualized dividend amount of $1.22 per share. The dividend is payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date.
Record Date
Payment Date
Amount
July 18, 2025
July 31, 2025
$0.10167 per common share
August 18, 2025
August 29, 2025
$0.10167 per common share
September 19, 2025
September 30, 2025
$0.10167 per common share
Expand
NORTHSIDE OUTPATIENT MEDICAL DEVELOPMENTS
During the second quarter of 2025, Healthpeak entered into two new outpatient development agreements in high-growth submarkets of Atlanta totaling $148 million to support the expansion of our longstanding partner, Northside Hospital. Affiliates of Northside have pre-leased 78% of each building for a range of clinical services, reflecting the system's continued investment in outpatient capacity across two premier campuses. Physician tenants will have the ability to co-invest in the buildings. Upon stabilization, Healthpeak expects to achieve cash yields in the mid-7% range.
Northside Forsyth: $82 million, 118,000 square foot Class A outpatient medical building and accompanying parking deck located on the campus of Northside Hospital Forsyth, a 389-bed acute care hospital located in Cumming, Georgia, a northeastern suburb of Atlanta.
Northside Cherokee: $66 million, 148,000 square foot Class A outpatient medical building located on the campus of Northside Hospital Cherokee, a 332-bed acute care hospital in Canton, Georgia, a northern suburb of Atlanta.
SHARE REPURCHASE ACTIVITY
As previously disclosed, in April 2025, Healthpeak repurchased 3.9 million shares at a weighted average share price of $18.22, totaling $72 million.
As of July 24, 2025, approximately $406 million remained available for share repurchases under the program.
BALANCE SHEET
In June 2025, Healthpeak repaid $452 million 4.0% senior notes at maturity.
As of July 24, 2025, Healthpeak had approximately $2.3 billion in available liquidity through a combination of unrestricted cash and its revolving credit facility.
2025 GUIDANCE
We are reaffirming the following guidance ranges for full year 2025:
Diluted FFO as Adjusted per share of $1.81 – $1.87
Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 3.0% – 4.0%
We are updating the following guidance ranges for full year 2025:
Diluted earnings per common share from $0.30 – $0.36 to $0.25 – $0.31
Diluted Nareit FFO per share from $1.81 – $1.87 to $1.78 – $1.84
These estimates are based on our current view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2025. For additional details and assumptions, please see page 12 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at
CONFERENCE CALL INFORMATION
Healthpeak has scheduled a conference call and webcast for Friday, July 25, 2025, at 8:00 a.m. Mountain Time.
The conference call can be accessed in the following ways:
An archive of the webcast will be available on Healthpeak's website through July 24, 2026, and a telephonic replay can be accessed through August 1, 2025, by dialing (800) 770-2030 and entering conference ID number 95156.
ABOUT HEALTHPEAK
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery.
FORWARD-LOOKING STATEMENTS
Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, developments, redevelopments, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2025 Guidance Information." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends that may increase construction, labor and other operating costs; changes within the life science industry; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants', operators', or borrowers' ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, which can render a project less profitable or unprofitable and delay or prevent its undertaking or completion; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with our senior housing properties managed by third parties, including our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as 'RIDEA'); economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses; our use of joint ventures may limit our returns on and our flexibility with jointly owned investments; our use of rent escalators or contingent rent provisions in our leases; competition for suitable healthcare properties to grow our investment portfolio; our ability to exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions or internalize property management; the potential impact of unfavorable resolution of litigation or disputes and resulting rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; our ability to satisfy environmental, social and governance and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including the coronavirus disease (Covid), and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology and any material failure, inadequacy, interruption, or security failure of that technology; the use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all; an increase in our level of indebtedness; covenants in our debt instruments, which may limit our operational flexibility, and breaches of these covenants; volatility in the market price and trading volume of our common stock; adverse changes in our credit ratings; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the Coronavirus, Aid, Relief and Economic Security Act Provider Relief Fund and other Covid-related stimulus and relief programs; changes in federal, state, or local laws or regulations that may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate; our ability to successfully integrate our operations with Physicians Realty Trust and realize the anticipated synergies of our merger with Physicians Realty Trust and benefits of property management internalization; our ability to maintain our qualification as a real estate investment trust ('REIT'); our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from 'prohibited transactions'; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; tax protection agreements that may limit our ability to dispose of certain properties and may require us to maintain certain debt levels; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC ('Healthpeak OP') common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings.
Moreover, other risks and uncertainties of which we are not currently aware may also affect our forward-looking statements, and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We do not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Healthpeak Properties, Inc.
Consolidated Statements of Operations
In thousands, except per share data
Three Months Ended
June 30,
Six Months Ended
June 30,
2025
2024
2025
2024
Revenues:
Rental and related revenues
$
529,687
$
546,781
$
1,067,828
$
1,008,814
Resident fees and services
148,855
140,891
297,782
279,667
Interest income and other
15,806
7,832
31,627
13,583
Total revenues
694,348
695,504
1,397,237
1,302,064
Costs and expenses:
Interest expense
75,063
74,910
147,756
135,817
Depreciation and amortization
265,916
283,498
534,462
502,717
Operating
276,181
273,827
549,324
517,556
General and administrative
20,764
26,718
46,882
50,017
Transaction and merger-related costs
10,215
7,759
15,749
114,979
Impairments and loan loss reserves (recoveries), net
3,499
(553
)
(63
)
10,905
Total costs and expenses
651,638
666,159
1,294,110
1,331,991
Other income (expense):
Gain (loss) on sales of real estate, net
1,636
122,044
1,636
125,299
Other income (expense), net
(4,692
)
4,004
(10,818
)
82,520
Total other income (expense), net
(3,056
)
126,048
(9,182
)
207,819
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures
39,654
155,393
93,945
177,892
Income tax benefit (expense)
(2,382
)
(2,728
)
(4,462
)
(16,426
)
Equity income (loss) from unconsolidated joint ventures
1,747
51
(400
)
2,427
Net income (loss)
39,019
152,716
89,083
163,893
Noncontrolling interests' share in earnings
(7,346
)
(6,669
)
(14,582
)
(11,170
)
Net income (loss) attributable to Healthpeak Properties, Inc.
31,673
146,047
74,501
152,723
Participating securities' share in earnings
(115
)
(214
)
(579
)
(414
)
Net income (loss) applicable to common shares
$
31,558
$
145,833
$
73,922
$
152,309
Earnings (loss) per common share:
Basic
$
0.05
$
0.21
$
0.11
$
0.23
Diluted
$
0.05
$
0.21
$
0.11
$
0.23
Weighted average shares outstanding:
Basic
695,188
702,382
697,117
651,642
Diluted
695,194
703,268
697,146
652,113
Expand
Healthpeak Properties, Inc.
Funds From Operations
In thousands, except per share data
Three Months Ended
June 30,
Six Months Ended
June 30,
2025
2024
2025
2024
Net income (loss) applicable to common shares
$
31,558
$
145,833
$
73,922
$
152,309
Real estate related depreciation and amortization
265,916
283,498
534,462
502,717
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures
12,530
11,621
24,730
20,393
Noncontrolling interests' share of real estate related depreciation and amortization
(4,426
)
(4,732
)
(8,879
)
(9,174
)
Loss (gain) on sales of depreciable real estate, net
(1,636
)
(122,044
)
(1,636
)
(125,299
)
Loss (gain) upon change of control, net (1)
—
(198
)
—
(77,978
)
Taxes associated with real estate dispositions (2)
(335
)
49
(335
)
11,657
Nareit FFO applicable to common shares
303,607
314,027
622,264
474,625
Distributions on dilutive convertible units and other
4,560
4,583
9,183
5,281
Diluted Nareit FFO applicable to common shares
$
308,167
$
318,610
$
631,447
$
479,906
Diluted Nareit FFO per common share
$
0.43
$
0.44
$
0.89
$
0.72
Weighted average shares outstanding - Diluted Nareit FFO
709,839
717,797
711,828
661,999
Impact of adjustments to Nareit FFO:
Transaction and merger-related items (3)
$
10,215
$
3,369
$
15,749
$
106,198
Other impairments (recoveries) and other losses (gains), net (4)
3,499
(553
)
179
11,300
Casualty-related charges (recoveries), net (5)
3,919
(1,204
)
8,145
(1,204
)
Total adjustments
17,633
1,612
24,073
116,294
FFO as Adjusted applicable to common shares
321,240
315,639
646,337
590,919
Distributions on dilutive convertible units and other
4,545
4,581
9,161
6,960
Diluted FFO as Adjusted applicable to common shares
$
325,785
$
320,220
$
655,498
$
597,879
Diluted FFO as Adjusted per common share
$
0.46
$
0.45
$
0.92
$
0.90
Weighted average shares outstanding - Diluted FFO as Adjusted
709,839
717,797
711,828
664,325
Expand
_______________________________________
(1)
The six months ended June 30, 2024 includes a gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations.
(2)
The six months ended June 30, 2024 includes non-cash income tax expense related to the sale of a 65% interest in two lab buildings in San Diego, California.
(3)
The three and six months ended June 30, 2025 and 2024 includes costs related to the merger, which are primarily comprised of advisory, legal, accounting, tax, information technology, post-combination severance and stock compensation expense, and other costs of combining operations with Physicians Realty Trust that were incurred during the period. The three and six months ended June 30, 2025 also includes $6 million of costs incurred related to investments we are no longer pursuing. For the three and six months ended June 30, 2024, these costs were partially offset by termination fee income of $4 million and $9 million, respectively, associated with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024, for which the lease terms were modified to accelerate expiration of the lease to December 2024. This termination fee income is included in rental and related revenues on the Consolidated Statements of Operations, but is excluded from Portfolio Cash Real Estate Revenues and FFO as Adjusted.
(4)
The three and six months ended June 30, 2025 and 2024 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.
(5)
Casualty-related charges (recoveries), net are recognized in other income (expense), net, equity income (loss) from unconsolidated joint ventures, and noncontrolling interests' share in earnings in the Consolidated Statements of Operations.
Expand
Healthpeak Properties, Inc.
Adjusted Funds From Operations
In thousands, except per share data
Three Months Ended
June 30,
Six Months Ended
June 30,
2025
2024
2025
2024
FFO as Adjusted applicable to common shares
$
321,240
$
315,639
$
646,337
$
590,919
Stock-based compensation amortization expense
1,738
4,814
6,365
8,180
Amortization of deferred financing costs and debt discounts (premiums)
7,875
7,317
15,727
11,840
Straight-line rents
(5,401
)
(10,453
)
(16,554
)
(22,545
)
AFFO capital expenditures
(25,729
)
(35,718
)
(48,864
)
(53,235
)
CCRC entrance fees (1)
19,042
12,117
23,739
19,502
Deferred income taxes
2,597
1,021
5,168
1,745
Amortization of above (below) market lease intangibles, net
(10,085
)
(8,086
)
(20,296
)
(15,437
)
Other AFFO adjustments
(1,069
)
(2,169
)
381
(3,667
)
AFFO applicable to common shares
310,208
284,482
612,003
537,302
Distributions on dilutive convertible units and other
4,560
4,582
9,182
6,799
Diluted AFFO applicable to common shares (1)
$
314,768
$
289,064
$
621,185
$
544,101
Diluted AFFO per common share (1)
$
0.44
$
0.40
$
0.87
$
0.82
Weighted average shares outstanding - Diluted AFFO
709,839
717,797
711,828
663,975
Expand
_______________________________________
(1)
During the first quarter of 2025, we changed our definition of AFFO to adjust for the non-refundable entrance fees collected in excess of the related amortization as we believe the cash collection of these fees is a more meaningful representation of the performance of CCRCs in the determination of AFFO. Utilizing the prior definition for the three months ended June 30, 2025 and 2024, diluted AFFO applicable to common shares was $295.7 million and $276.9 million, respectively, and diluted AFFO per common share was $0.42 and $0.39, respectively. Utilizing the prior definition for the six months ended June 30, 2025 and 2024, diluted AFFO applicable to common shares was $597.4 million and $524.6 million, respectively, and diluted AFFO per common share was $0.84 and $0.79, respectively.
Expand
